NASDAQ:IMAB I-Mab (IMAB) Stock Price, News & Analysis $1.22 +0.02 (+1.67%) (As of 08:34 AM ET) Add Compare Share Share Today's Range$1.22▼$1.2250-Day Range$1.05▼$1.8652-Week Range$0.99▼$2.54Volume113 shsAverage Volume334,515 shsMarket Capitalization$98.68 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get I-Mab alerts: Email Address I-Mab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside920.8% Upside$12.25 Price TargetShort InterestHealthy1.15% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.13) to ($1.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.25 out of 5 starsMedical Sector489th out of 924 stocksPharmaceutical Preparations Industry224th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingI-Mab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageI-Mab has received no research coverage in the past 90 days.Read more about I-Mab's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.15% of the outstanding shares of I-Mab have been sold short.Short Interest Ratio / Days to CoverI-Mab has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in I-Mab has recently decreased by 11.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldI-Mab does not currently pay a dividend.Dividend GrowthI-Mab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMAB. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for I-Mab this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for IMAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, I-Mab insiders have not sold or bought any company stock.Percentage Held by Insiders22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.38% of the stock of I-Mab is held by institutions.Read more about I-Mab's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for I-Mab are expected to grow in the coming year, from ($2.13) to ($1.70) per share.Price to Book Value per Share RatioI-Mab has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about I-Mab's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About I-Mab Stock (NASDAQ:IMAB)I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Read More IMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMAB Stock News HeadlinesAugust 21 at 1:50 AM | americanbankingnews.comI-Mab (IMAB) Set to Announce Quarterly Earnings on WednesdayAugust 14, 2024 | prnewswire.comI-Mab to Release 1H 2024 Financial Results on August 28, 2024August 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. August 7, 2024 | prnewswire.comI-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)July 15, 2024 | prnewswire.comI-Mab Announces Leadership TransitionsJune 5, 2024 | prnewswire.comI-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal CancersMay 23, 2024 | globenewswire.comI-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024May 22, 2024 | prnewswire.comI-Mab to Participate at the Jefferies Global Healthcare ConferenceAugust 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. April 30, 2024 | prnewswire.comI-MAB Filed 2023 Annual Report on Form 20-FApril 16, 2024 | msn.comOmega Therapeutics CFO Joshua Reed to departApril 12, 2024 | markets.businessinsider.comI-MAB Buy Rating Justified by Strong Leadership and Promising PipelineApril 5, 2024 | prnewswire.comI-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | investing.comI-Mab completes divestiture of its Shanghai unit for $80 millionApril 2, 2024 | uk.finance.yahoo.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaApril 2, 2024 | prnewswire.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaMarch 18, 2024 | finance.yahoo.comI-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 14, 2024 | finance.yahoo.comI-Mab Reports Full Year 2023 Financial Results and Business UpdateSee More Headlines Receive IMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today8/22/2024Next Earnings (Confirmed)8/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMAB CUSIPN/A CIK1778016 Webwww.i-mabbiopharma.com Phone86-21-6057-8000FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+920.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.67 Quick Ratio5.67 Sales & Book Value Annual Sales$27.64 million Price / Sales3.51 Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book0.41Miscellaneous Outstanding Shares80,883,000Free Float63,008,000Market Cap$97.06 million OptionableOptionable Beta1.08 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Raj Kannan (Age 60)CEO & Director Dr. Jerry WangCo-Founder & Chief Scientific OfficerMr. Skelton JosephChief Financial OfficerMr. Tianyi ZhangVice President of Investor RelationsDr. Fernando J. Salle´s Ph.D.Senior VP and Head of U.S. & EU Business DevelopmentClaire XuHead of US siteMs. Min Yin (Age 54)Senior Vice President of Operations Dr. Louie Naumovski M.D.Ph.D., Interim Chief Medical OfficerMr. Tyler EhlerSenior Director of Investor RelationsMore ExecutivesKey CompetitorsVoyager TherapeuticsNASDAQ:VYGRAura BiosciencesNASDAQ:AURAG1 TherapeuticsNASDAQ:GTHXLyell ImmunopharmaNASDAQ:LYELTourmaline BioNASDAQ:TRMLView All CompetitorsInstitutional OwnershipBank of Montreal CanBought 244,875 shares on 8/14/2024Ownership: 0.303%XTX Topco LtdSold 12,609 shares on 8/12/2024Ownership: 0.022%View All Institutional Transactions IMAB Stock Analysis - Frequently Asked Questions How have IMAB shares performed this year? I-Mab's stock was trading at $1.90 at the beginning of the year. Since then, IMAB stock has decreased by 36.8% and is now trading at $1.20. View the best growth stocks for 2024 here. When did I-Mab IPO? I-Mab (IMAB) raised $100 million in an initial public offering on Thursday, January 16th 2020. The company issued 7,400,000 shares at $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers. Who are I-Mab's major shareholders? Top institutional shareholders of I-Mab include Bank of Montreal Can (0.30%) and XTX Topco Ltd (0.02%). How do I buy shares of I-Mab? Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of I-Mab own? Based on aggregate information from My MarketBeat watchlists, some other companies that I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO) and Enterprise Products Partners (EPD). This page (NASDAQ:IMAB) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredSilver Grab of the Decade?In a groundbreaking move, J.P. Morgan now possesses the largest amount of physical silver in recorded history…...Colonial Metals | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
